Emerging role of the cannabinoid receptor CB 2 in immune regulation: Therapeutic prospects for neuroinflammation

Expert Reviews in Molecular Medicine

Volumn 11, Issue , 2009, Pages

  Cabral, Guy A ^a   Griffin Thomas, LaToya ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 2 RECEPTOR;

AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; INFLAMMATION; MOLECULAR GENETICS; NERVOUS SYSTEM; PATHOLOGY; PHYSIOLOGY; RESEARCH; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; INFLAMMATION; MOLECULAR SEQUENCE DATA; NERVOUS SYSTEM; NEUROIMMUNOMODULATION; RECEPTOR, CANNABINOID, CB2; RESEARCH;

EID: 63049105150     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399409000957     Document Type: Review

References (181)

1. Gauthier, K.M. et al. (2005) Endothelium-derived 2-arachidonylglycerol: an intermediate in vasodilatory eicosanoid release in bovine coronary arteries. American Journal of Physiology - Heart and Circulatory Physiology 288, H1344-H1351 (Pubitemid 40270043)
2. Gonthier, M-P. et al. (2007) Identification of endocannabinoids and related compounds in human fat cells. Obesity 15, 837-845 (Pubitemid 46740958)
3. Walter, L. et al. (2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. Journal of Neuroscience 23, 1398-1405 (Pubitemid 36258918)
4. Di Marzo, V. et al. (1999) Biosynthesis and inactivation of the endocannabinoid 2- arachidonoylglycerol in circulating and tumoral macrophages. European Journal of Biochemistry 264, 258-267 (Pubitemid 29385890)
5. Maejima, T. et al. (2001) Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron 31, 463-475 (Pubitemid 32778564)
6. Devane,W.A. et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949 (Pubitemid 23026736)
7. Mechoulam, R. et al. (1995) Identification of an endogenous 2-monoglyceride present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology 50, 83-90
8. Dinh, T.P. et al. (2002a) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proceedings of the National Academy of Sciences of the United States of America 99, 10819-10824
9. Dinh, T.P. et al. (2002b) A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chemistry and Physics of Lipids 121, 149-158 (Pubitemid 36044549)
10. Saario, S.M. et al. (2004) Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochemical Pharmacology, 67, 1381-1387 (Pubitemid 38324545)
11. DiMarzo,V. et al. (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686-691
12. Beltramo, M. et al. (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277, 1094-1097 (Pubitemid 27371630)
13. Rakhshan, F. et al. (2000) Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. Journal of Pharmacology and Experimental Therapeutics 292, 960-967 (Pubitemid 30136588)
14. Day, T.A. et al. (2001) Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Molecular Pharmacology 59, 1369-1375 (Pubitemid 32510100)
15. Gardner, B. et al. (2003) Methanandamide increases COX-2 expression and tumor growth in murine lung cancer. FASEB Journal 17, 2157-2159
16. Hinz, B. et al. (2004) R(+)-methanandamideinduced cyclooxygenase-2 expression in H4 human neuroglioma cells: possible involvement of membrane lipid rafts. Biochemical and Biophysical Research Communications 324, 621-626 (Pubitemid 39345561)
17. Oz, M. (2006) Receptor-independent actions of cannabinoids on cell membranes: Focus on endocannabinoids. Pharmacology and Therapeutics 111, 114-144
18. De Morrow, S. et al. (2007) Opposing actions of endocannabinoids on cholangiocarcinoma growth. Recruitment of Fas and Fas ligand to lipid rafts. Journal of Biological Chemistry 282, 13098-13113 (Pubitemid 47100640)
19. Howlett, A.C. and Fleming, R.M. (1984) Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Molecular Pharmacology 26, 532-538 (Pubitemid 15190717)
20. Howlett, A.C. (1985) Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Molecular Pharmacology 27, 429-436
21. Howlett, A.C., Qualy, J.M. and Khachatrian, L.L. (1986) Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Molecular Pharmacology 29, 307-313 (Pubitemid 16137598)
22. Matsuda, L.A. et al. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564
23. Herkenham, M. et al. (1990) Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences of the United States of America 87, 1932-1936
24. Westlake, T.M. et al. (1994) Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 63, 637-652 (Pubitemid 24360219)
25. Howlett, A.C. and Mukhopadhyay, S. (2000) Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chemistry and Physics of Lipids 108, 53-70
26. Demuth, D.G. and Molleman, A. (2006) Cannabinoid signalling. Life Sciences 78, 546-563
27. Gifford, A.N. et al. (2002) In vivo imaging of the brain cannabinoid receptor. Chemistry and Physics of Lipids 121, 65-72 (Pubitemid 36044543)
28. Munro, S., Thomas, K.L. and Abu-Shaar,M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65 (Pubitemid 23305569)
29. Griffin, G. et al. (2000) Cloning and pharmacological characterization of the rat CB2 cannabinoid receptor. Journal of Pharmacology and Experimental Therapeutics 292, 888-894
30. Brown, S.M. et al. (2002) Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochimica et Biophysica Acta 1576, 255-264 (Pubitemid 34655768)
31. Bouaboula, M. et al. (1999) Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR144528. Implications for receptor biological responses. Journal of Biological Chemistry 274, 20397-20405
32. Galiegue, S. et al. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. European Journal of Biochemistry 232, 54-61
33. Schatz, A.R. et al. (1997) Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicology and Applied Pharmacology 142, 278-287 (Pubitemid 28381018)
34. Nunez, E. et al. (2004) Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse 53, 208-213 (Pubitemid 39045539)
35. Ramirez, B.G. et al. (2005) Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. Journal of Neuroscience 25, 1904-1913 (Pubitemid 40289395)
36. Cabral, G.A. and Marciano-Cabral, F. (2005) Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. Journal of Leukocyte Biology 78, 1192-1197 (Pubitemid 41779223)
37. Fernandez-Ruiz, J. et al. (2007) Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends in Pharmacological Sciences 28, 39-45 (Pubitemid 46038536)
38. Sawzdargo, M. et al. (1999) Identification and cloning of three novel human G proteincoupledreceptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Molecular Brain Research 64, 193-198 (Pubitemid 29052470)
39. Baker, D. et al. (2006) In silico patent searching reveals a new cannabinoid receptor. Trends in Pharmacological Sciences 27, 1-4 (Pubitemid 43063115)
40. Pertwee, R.G. (2007) GPR55: a new member of the cannabinoid receptor clan? British Journal of Pharmacology 152, 984-986
41. Ryberg, E. et al. (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology 152, 1092-1101 (Pubitemid 350166046)
42. Lauckner, J.E. et al. (2008) GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proceedings of the National Academy of Sciences of the United States of America 105, 2699-2704 (Pubitemid 351520576)
43. Caterina, M.J. et al. (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389, 816-824 (Pubitemid 27462969)
44. Szallasi, A. (2002)Vanilloid (capsaicin) receptors in health and disease. American Journal of Clinical Pathology 118, 110-121
45. Melck, D. et al. (1999) Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamidefacilitated transport and bind to CB1 cannabinoid receptors. Biochemical and Biophysical Research Communications 262, 275-284 (Pubitemid 29412660)
46. Zygmunt, P.M. et al. (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452-457 (Pubitemid 29361798)
47. Smart, D. et al. (2000) The endogenous lipid anandamide is a full agonist at thehumanvanilloid receptor (hVR1). British Journal of Pharmacology 129, 227-230 (Pubitemid 30072640)
48. Ross, R.A. (2003) Anandamide and vanilloid TRVP1 receptors. British Journal of Pharmacology 140, 790-801
49. Jarai, Z. et al. (1999) Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proceedings of the National Academy of Sciences of the United States of America 96, 14136-14141
50. Di Marzo, V. et al. (2000) Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. Journal of Neurochemistry 75, 2434-2444
51. Breivogel, C.S. et al. (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Molecular Pharmacology 60, 155-163 (Pubitemid 32595243)
52. Wiley, J.L. and Martin, B.D. (2002) Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chemistry and Physics of Lipids 121, 57-63 (Pubitemid 36044542)
53. Bayewitch, M. et al. (1995) The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Letters 375, 143-147
54. Slipetz, D.M. et al. (1995) Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Molecular Pharmacology 48, 352-361
55. Bouaboula, M. et al. (1996) Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. European Journal of Biochemistry 237, 704-711
56. Zoratti, C. et al. (2003)Anandamide initiates Ca(2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells. British Journal of Pharmacology 140, 1351-1362 (Pubitemid 38067842)
57. Cabral, G.A. et al. (2008) CB2 receptors in the brain: role in central immune function. British Journal of Pharmacology 153, 240-251
58. Cabral, G.A. and Staab, A. (2005) Effects on the immune system. Handbook of Experimental Pharmacology 168, 385-423
59. Morahan,P.S. et al. (1979)Effects of cannabinoids on host resistance to Listeria monocytogenes and herpes simplex virus. Infection and Immunity 23, 670-674 (Pubitemid 9138968)
60. Juel-Jensen, B.E. (1972) Cannabis and recurrent herpes simplex. British Medical Journal. 4, 296
61. Cabral, G.A. and Dove-Pettit, D.A. (1998) Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. Journal of Neuroimmunology 83, 116-123 (Pubitemid 28280957)
62. Klein, T.W., Newton, C. and Friedman, H. (1998) Cannabinoid receptors and immunity. Immunology Today 19, 373-381
63. Arata, S. et al. (1992) Enhanced growth of Legionella pneumophila in tetrahydrocannabinol-treated macrophages. Proceedings of the Society for Experimental Biology and Medicine 199, 65-67
64. Arata, S. et al. (1991) Tetrahydrocannabinol treatment suppresses growth restriction of Legionella pneumophila in murine macrophage cultures. Life Sciences 49, 473-479
65. Marciano-Cabral, F. et al. (2001) Delta-9- tetrahydrocannabinol (THC), the major psychoactive component of marijuana, exacerbates brain infection by Acanthamoeba. Journal of Eukaryotic Microbiology (Suppl), 4S-5S (Pubitemid 34281056)
66. Newton, C.A., Klein, T. and Friedman, H. (1994) Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9- tetrahydrocannabinol injection. Infection and Immunity 62, 4015-4020 (Pubitemid 24264350)
67. Burnette-Curley, D. and Cabral, G.A. (1995) Differential inhibition of RAW264.7 macrophage tumoricidal activity by delta 9tetrahydrocannabinol. Proceedings of the Society for Experimental Biology and Medicine 210, 64-76
68. Coffey, R.G. et al. (1996) Tetrahydrocannabinol inhibition of macrophage nitric oxide production. Biochemical Pharmacology 52, 743-751 (Pubitemid 26276490)
69. Klein, T.W. et al. (1991) Marijuana components suppress induction and cytolytic function of murine cytotoxic Tcells in vitro and in vivo. Journal of Toxicology and Environmental Health 32, 465-477
70. McCoy, K.L. et al. (1999) Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. Journal of Pharmacology and Experimental Therapeutics 289, 1620-1625 (Pubitemid 29246698)
71. Raborn, E.S. et al. (2008) The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/ CCL5: linkage to the CB(2) receptor. Journal of Neuroimmune Pharmacology 3, 117-129
72. Sacerdote, P. et al. (2000) In vivo and in vitro treatmentwith the synthetic cannabinoid CP55, 940 decrease the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. Journal of Neuroimmunology 109, 155-163
73. Ullrich, O. et al. (2007) Immune control by endocannabinoids - new mechanisms of neuroprotection? Journal of Neuroimmunology 184, 127-135 (Pubitemid 46365996)
74. Cabral, G.A. and Marciano-Cabral, F. (2004) Cannabinoid-mediated exacerbation of brain infection by opportunistic amebae. Journal of Neuroimmunology 147, 127-130 (Pubitemid 38114962)
75. Steffens, S. et al. (2005) Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434, 782-786 (Pubitemid 44739523)
76. Kishimoto, S. et al. (2003) 2-arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism. Journal of Biological Chemistry 278, 24469-24475 (Pubitemid 37548598)
77. Derocq, J. et al. (1995) Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Letters 369, 177-182
78. Carayon, P. et al. (1998) Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. Blood 92, 3605-3615 (Pubitemid 28525186)
79. Friedman, H. et al. (1991) Immunosuppression by marijuana components. In Psychoneuroimmunology (Ader, R., Felten, D.L. and Cohen, N., eds.), pp. 931-953, Academic Press
80. Klein, T. et al. (1998b) Marijuana, immunity and infection. Journal of Neuroimmunology 83, 102-115 (Pubitemid 28280956)
81. Kaminski, N. et al. (1994) Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. Biochemical Pharmacology 48, 1899-1908 (Pubitemid 24355018)
82. Massi, P. et al. (2000) Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity. European Journal of Pharmacology 387, 343-347 (Pubitemid 30067837)
83. Klein, T.W. et al. (2000) Delta-9- tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. Journal of Immunology 164, 6461-6466 (Pubitemid 30408829)
84. Zhu, L.X. et al. (2000)Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. Journal of Immunology 165, 373-380 (Pubitemid 30429529)
85. Berdyshev, E.V. et al. (1997) Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. European Journal of Pharmacology 330, 231-240 (Pubitemid 27296727)
86. Facci, L. et al. (1995) Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proceedings of the National Academy of Sciences of the United States of America 92, 3376-3380
87. Joseph, J. et al. (2004) Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunology, Immunotherapy 53, 723-728 (Pubitemid 38962066)
88. Valk, P. et al. (1997) Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells. Blood 90, 1448-1457 (Pubitemid 27355416)
89. Molina-Holgado, F. et al. (1998) The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptormediated pathway. FEBS Letters 433, 139-142 (Pubitemid 28386745)
90. Stefano, G.B. et al. (2000) 2-Arachidonyl-glycerol stimulates nitric oxide release from human immune and vascular tissues and invertebrate immunocytes by cannabinoid receptor 1. Pharmacological Research 42, 317-322
91. Jorda, M.A. et al. (2002) Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood 99, 2786-2793 (Pubitemid 34525366)
92. Rayman, N. et al. (2004) Distinct expression profiles of the peripheral cannabinoid receptor in lymphoid tissues depending on receptor activation status. Journal of Immunology 172, 2111-2117 (Pubitemid 38182356)
93. Kishimoto, S. et al. (2004) 2-Arachidonoylglycerol an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. Journal of Biochemistry (Tokyo) 135, 517-524 (Pubitemid 38660939)
94. Carrier, E.J. et al. (2004) Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Molecular Pharmacology 65, 999-1007 (Pubitemid 38420506)
95. Klein, T.W. and Friedman, H. (1990) Modulation of murine immune cell function by marijuana components. In Drugs of Abuse and Immune Function (Watson, R., ed.), pp. 87-111, CRC Press
96. Burnette-Curley, D. et al. (1993) Delta-9- tetrahydrocannabinol inhibits cell contact-dependent cytotoxicityof BacillusCalmette- Guerin-activated macrophages. International Journal of Immunopharmacology 15, 371-382 (Pubitemid 23153548)
97. Cabral, G.A. and Mishkin, E.M. (1989) Delta-9- tetrahydrocannabinol inhibits macrophage protein expression in response to bacterial immunomodulators. Journal of Toxicology and Environmental Health 26, 175-182 (Pubitemid 19083890)
98. Watzl, B. et al. (1991) Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro. In Advances in Experimental Medicine and Biology (Friedman, H., Specter, S. and Klein, T.W., eds), pp. 63-70, Plenum Press
99. Nakano, Y. et al. (1992) Modulation of interleukin 2 activity by delta 9-tetrahydrocannabinol after stimulation with concanavalin A, phytohemagglutinin, or anti-CD3 antibody. Proceedings of the Society for Experimental Biology and Medicine 201, 165-168
100. Puffenbarger, R.A. et al. (2000) Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 29, 58-69 (Pubitemid 30031134)
101. Jeon,Y.J. et al. (1996) Attenuation of inducible nitric oxide synthase gene expression by delta9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-kB/Rel activation. Molecular Pharmacology 50, 334-341 (Pubitemid 26265138)
102. Adams, D.O. and Hamilton, T.A. (1984) The cell biology of macrophage activation. Annual Review of Immunology 2, 283-318
103. Hamilton, T.A. and Adams, D.O. (1987) Molecular mechanisms of signal transduction in macrophages. Immunology Today 8, 151-158 (Pubitemid 17078378)
104. Hamilton, T.A. et al. (1986) Effects of bacterial lipopolysaccharide on protein synthesis in murine peritoneal macrophages: Relationship to activation for macrophage tumoricidal function. Journal of Cellular Physiology 128, 9-17 (Pubitemid 16099454)
105. Carlisle, S. et al. (2002) Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. International Immunopharmacology 2, 69-82 (Pubitemid 33086805)
106. Harris, H. (1953) Chemotaxis of monocytes. British Journal of Experimental Pathology 34, 276-279
107. Harris, H. (1954) Role of chemotaxis in inflammation. Physiological Reviews 34, 529-562
108. Jin, T. and Hereld, D. (2006) Moving toward understanding eukaryotic chemotaxis. European Journal of Cell Biology 85, 905-913 (Pubitemid 44317598)
109. Kehrl, J.H. (2006) Chemoattractant receptor signaling and the control of lymphocyte migration. Immunologic Research 34, 211-227
110. Becker, E.L. (1977) Stimulated neutrophil locomotion: chemokinesis and chemotaxis. Archives of Pathology and Laboratory Medicine 101, 509-513
111. Keller, H.U. et al. (1978) Distinct chemokinetic and chemotactic responses in neutrophil granulocytes. European Journal of Immunology 8, 1-7 (Pubitemid 8312468)
112. Lauffenburger, D.A. and Horwitz, A.F. (1996) Cell migration: a physically integrated molecular process. Cell 84, 359-369 (Pubitemid 26058561)
113. Mitchison, T.J. and Cramer, L.P. (1996) Actin-based cell motility and cell locomotion. Cell 84, 371-379 (Pubitemid 26058562)
114. Murdoch, C. and Finn, A. (2000) Chemokine receptors and their role in inflammation and infectious disease. Blood 95, 3032-3043 (Pubitemid 30321151)
115. Schiffmann, E. et al. (1975) N-formyl-methionyl peptides as chemoattractants for leucocytes. Proceedings of the National Academy of Sciences of the United States of America 72, 1059-1062
116. Goldman, D.W. and Goetzl, E.J. (1982) Specific binding of leukotriene B4 to receptors on human polymorphonuclear leukocytes. Journal of Immunology 129, 1600-1604 (Pubitemid 12031098)
117. Hanahan, D.J. (1986) Platelet activating factor: A biologically active phosphoglyceride. Annual Review of Biochemistry 55, 483-509
118. Gerard, C. and Gerard, N.P. (1994) C5A anaphylatoxin and its seven transmembranesegment receptor. Annual Review of Immunology 12, 775-808 (Pubitemid 24140431)
119. Baggiolini, M. et al. (1994) Interleukin-8 and related chemotactic cytokines CXC and CC chemokines. Advances in Immunology 55, 97-179
120. Baggiolini, M. et al. (1997) Human chemokines: an update.Annual Reviewof Immunology 15, 675-705 (Pubitemid 27169296)
121. Kim, C.H. (2004) Chemokine-chemokine receptor network in immune cell trafficking. Current Drug Targets - Immune, Endocrine & Metabolic Disorders 4, 343-361
122. Le, Y. et al. (2004) Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell Molecular Immunology 1, 95-104
123. Charo, I.F. and Ransohoff, R.M. (2006) Mechanisms of disease: the many roles of chemokines and chemokine receptors in inflammation. New England Journal of Medicine 354, 610-621 (Pubitemid 43209108)
124. Sacerdote, P. et al. (2005) The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. Journal of Neuroimmunology 159, 97-105 (Pubitemid 40126181)
125. Buckley, N.E. et al. (2000) Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. European Journal of Pharmacology 396, 141-149 (Pubitemid 30265571)
126. Buckley, N.E. (2008) The peripheral cannabinoid receptor knockout mice: an update. European Journal of Pharmacology 153, 309-318
127. Van Sickle, M.D. et al. (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310, 329-332 (Pubitemid 41457202)
128. Gong, J-P. et al. (2006) Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain. Brain Research 1071, 10-23 (Pubitemid 43255471)
129. Onaivi, E.S. (2006) Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology 54, 231-246
130. Onaivi, E.S. et al. (2006) Discovery of the presence and functional expression of cannabinoid CB2 receptors in the brain. Annals of the New York Academy of Sciences 1074, 514-536 (Pubitemid 44532857)
131. Grimsey, N.L. et al. (2008) Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal! Journal of Neuroscience Methods 171, 78-86
132. Shohami, E. et al. (1997) Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. Journal of Neuroimmunology 72, 169-177 (Pubitemid 27062773)
133. Cabral, G.A. et al. (2001) Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: evidence for CB1 receptor participation. Advances in Experimental Medicine and Biology 493, 207-214 (Pubitemid 34020229)
134. Molina-Holgado, F. et al. (2002) Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharideinduced nitric oxide release in astrocyte cultures. Journal of Neuroscience Research 67, 829-836 (Pubitemid 34226296)
135. Klegeris, A. et al. (2003) Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. British Journal of Pharmacology 139, 775-786 (Pubitemid 36819605)
136. Sheng, W.S. et al. (2005) Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 49, 211-219 (Pubitemid 40188500)
137. Kreutzberg, G.W. (1996) Microglia: a sensor for pathological events in the CNS. Trends in Neurosciences 19, 312-318
138. Benveniste, E.N. (1997) Role of macrophages/ microglia in multiple sclerosis and experimental allergic encephalomyelitis. Journal of Molecular Medicine 75, 165-173
139. Giulian, D. and Baker, T.J. (1986) Characterization of ameboid microglia isolated from developing mammalian brain. Journal of Neuroscience 6, 2163-2178 (Pubitemid 16043659)
140. Dickson, D.W. (1997) Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies. Neurobiology of Aging 18, S21-S26
141. Selkoe, D.J. (1998) The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends in Cell Biology 8, 447-453
142. Velez-Pardo, C. and Del Rio, M.J. (2006)Avoidance of Abeta[(25-35)]/ (H2O2)-induced apoptosis in lymphocytes by the cannabinoid agonists CP55,940 and JWJ-015 via receptor-independent and PI3K-dependedent mechanisms: role of NF-kappaB and p53. Medicinal Chemistry 2, 471-479 (Pubitemid 44389012)
143. Raine, C.S. and Wu, E. (1993) Multiple sclerosis: remyelination in acute lesions. Journal of Neuropathology and Experimental Neurology 52, 199-204 (Pubitemid 23136018)
144. Racke, M.K. (2001) Experimental autoimmune encephalomyelitis (EAE). Current Protocols in Neuroscience 9, Unit 9.7
145. Calderon, T.M. et al. (2006) A role for CXCL12 (SDF-1alpha) in the pathogenesis of multiple sclerosis: regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. Journal of Neuroimmunology 177, 27-39 (Pubitemid 44108231)
146. Kieseier, B.C. et al. (1999) Matrix metalloproteinases exhibit different expression patterns in inflammatory demyelinating diseases of the central and peripheral nervous system. Annals of the New York Academy of Sciences 878, 567-570 (Pubitemid 29353615)
147. Anthony, D.C. et al. (2000) The evidence for primary axonal loss in multiple sclerosis. Revue Neurologique 30, 1203-1208 (Pubitemid 30641122)
148. Yiangou, Y. et al. (2006) COX-2, CB2 and P2X7- immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord.BMC Neurology 6, 12
149. Fujiwara, M. and Egashira, N. (2004) New perspectives in the studies on endocannabinoid and cannabis: abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application. Journal of Pharmacological Sciences 96, 362-366 (Pubitemid 40144052)
150. Ehrhart, J. et al. (2005) Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. Journal of Neuroinflammation 2, 29
151. Sanchez, A.J. et al. (2006) R-(+)-[2,3-Dihydro-5- methyl-3-(4- morpholinylmethyl)-pyrrolo-[1,2,3- de]-1,4-benzoxazin-6-yl]-1- naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor. Biochemical Pharmacology 72, 1697-1706 (Pubitemid 44765005)
152. Palazuelos, J. et al. (2008) The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. Journal of Biological Chemistry 283, 13320-13329
153. Arevalo-Martin, A. et al. (2003) Therapeutic action of cannabinoids in a murine model of multiple sclerosis. Journal of Neuroscience 23, 2511-2516 (Pubitemid 36418583)
154. Croxford, J.L. and Miller, S.D. (2003) Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R + WIN55,212. Journal of Clinical Investigation 111, 1231-1240
155. Docagne, F. et al. (2007) Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation. Molecular and Cellular Neurosciences 34, 551-561
156. Kuncl, R.W. et al. (1992) Motor neuron disease. In Diseases of the Nervous System (2nd edn) (Asbury, A.K., McKhann, G.M. and McDonald, W.I., eds), pp. 1179-1208, W. B. Saunders
157. Babu, G.N. et al. (2008) Elevated inflammatory markers in a group of amyotrophic lateral sclerosis patients from northern India. Neurochemical Research 33, 1145-1149
158. Weydt, P. et al. (2005) Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 6, 182-184 (Pubitemid 41419206)
159. Bisland, L.G. et al. (2006) Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB Journal 20, 1003-1005
160. Shoemaker, J.L. et al. (2007) The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. Journal of Neurochemistry 101, 87-98 (Pubitemid 46426470)
161. Spencer, D.C. and Price, R.W. (1992) Human immunodeficiency virus and the central nervous system. Annual Review of Microbiology 46, 655-693
162. Benito, C. et al. (2005) A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virusinduced encephalitis. Journal of Neuroscience 25, 2530-2536 (Pubitemid 40365164)
163. Williams, K. et al. (2001a) Central nervous system perivascular cells are immunoregulatory cells that connect the CNS with the peripheral immune system. Glia 36, 156-164 (Pubitemid 33055904)
164. Williams, K.C. et al. (2001b) Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. Journal of Experimental Medicine 193, 905-915 (Pubitemid 32525863)
165. Ghosh, S. et al. (2006) Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Molecular Immunology 43, 2169-2179 (Pubitemid 43831198)
166. Rubio-Araiz, A. et al. (2008) The endocannabinoid system modulates a transient TNF pathway that induces neural stem cell proliferation. Molecular and Cellular Neurosciences 38, 374-380
167. Waksman, Y. et al. (1999) The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. Journal of Pharmacology and Experimental Therapeutics 288, 1357-1366 (Pubitemid 29254178)
168. Zhang, J. et al. (2003) Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. European Journal of Neuroscience 17, 2750-2754 (Pubitemid 36819300)
169. Benito, C. et al. (2007) Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. Journal of Neuroscience 27, 2396-2402 (Pubitemid 46340977)
170. Maresz, K. et al. (2005) Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. Journal of Neurochemistry 95, 437-445 (Pubitemid 41457512)
171. Ashton, J.C. et al. (2007) Cerebral hypoxiaischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neuroscience Letters 412, 114-117 (Pubitemid 46074356)
172. Benito, C. et al. (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in alzheimer's disease brains. Journal of Neuroscience 23, 11136-11141 (Pubitemid 37548949)
173. Carrier, E.J. et al. (2005) Endocannabinoids in neuroimmunology and stress. Current Drug Targets - CNS & Neurological Disorders 4, 657-665 (Pubitemid 41782627)
174. Marciano-Cabral, F. and Cabral, G.A. (2003) Acanthamoeba spp. as agents of disease in humans. Clinical Microbiology Reviews 16, 273-307 (Pubitemid 36519813)
175. Cabral, G.A. (2005) Lipids as bioeffectors in the immune system. Life Sciences 77, 1699-1710
176. Bouaboula, M. et al. (1993) Cannabinoid-receptor expression inhuman leukocytes. European Journal of Biochemistry 214, 173-180
177. Lee, S.F. et al. (2001a) Downregulation of cannabinoid receptor 2 (CB2) messenger RNA expression during in vitro stimulation of murine splenocytes with lipopolysaccharide. Advances in Experimental Medicine and Biology 493, 223-228
178. Lee, S.F. et al. (2001b) Differential expression of cannabinoid CB(2) receptor mRNA in mouse immune cell subpopulations and following B cell stimulation. European Journal of Pharmacology 423, 235-241 (Pubitemid 32614163)
179. Sinha, D. et al. (1998) Expression of the CB1 cannabinoid receptor in macrophage-like cells from brain tissue: immunochemical characterization by fusion protein antibodies. Journal of Neuroimmunology 82, 13-21 (Pubitemid 28129331)
180. Lynn, A.B. and Herkenham, M. (1994) Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. Journal of Pharmacology and Experimental Therapeutics 268, 1612-1623 (Pubitemid 24100385)
181. Kaminski, N.E. et al. (1992) Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoidmediated immune modulation. Molecular Pharmacology 42, 736-742 (Pubitemid 23021475)